Revance Therapeutics Inc. (NASDAQ:RVNC)’s share price traded down 3.3% during mid-day trading on Thursday . The stock traded as low as $14.60 and last traded at $14.66, with a volume of 55,833 shares changing hands. The stock had previously closed at $15.16.

Several equities analysts have issued reports on the stock. Zacks Investment Research cut shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 17th. Brean Capital reissued a “hold” rating on shares of Revance Therapeutics in a research note on Friday, August 5th. SunTrust Banks Inc. dropped their price objective on shares of Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, June 14th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $35.00 price objective (down from $54.00) on shares of Revance Therapeutics in a research note on Tuesday, June 14th. Finally, Guggenheim reissued a “buy” rating and issued a $55.00 price objective on shares of Revance Therapeutics in a research note on Tuesday, June 14th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $39.60.

The company has a 50 day moving average of $14.10 and a 200-day moving average of $16.67. The firm’s market cap is $400.20 million.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by $0.02. The company earned $0.80 million during the quarter, compared to analysts’ expectations of $0.06 million. The company’s revenue was up .0% compared to the same quarter last year. Equities research analysts anticipate that Revance Therapeutics Inc. will post ($3.53) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Revance Therapeutics stock. Schwab Charles Investment Management Inc. boosted its stake in Revance Therapeutics Inc. (NASDAQ:RVNC) by 35.5% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 63,467 shares of the biopharmaceutical company’s stock after buying an additional 16,625 shares during the period. Schwab Charles Investment Management Inc. owned 0.23% of Revance Therapeutics worth $2,169,000 as of its most recent SEC filing.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.